Order Article Reprints

Szemerédi N, Schelz Z, Horvath DA, Rácz B, Szatmári AG, Muddather HF, Bózsity N, Zupkó I, Spengler G. Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines. Pharmaceutics. 2024; 16(7):877. https://doi.org/10.3390/pharmaceutics16070877

Szemerédi, Nikoletta, Zsuzsanna Schelz, Dária Antónia Horvath, Bálint Rácz, András G. Szatmári, Hiba F. Muddather, Noémi Bózsity, István Zupkó, and Gabriella Spengler. 2024. "Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines" Pharmaceutics 16, no. 7: 877. https://doi.org/10.3390/pharmaceutics16070877

Szemerédi, N., Schelz, Z., Horvath, D. A., Rácz, B., Szatmári, A. G., Muddather, H. F., Bózsity, N., Zupkó, I., & Spengler, G. (2024). Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines. Pharmaceutics, 16(7), 877. https://doi.org/10.3390/pharmaceutics16070877